{"id":"W3212319088","doi":"10.1016/s2152-2650(21)02339-9","title":"P-212: DREAMM-5 platform trial: Belantamab mafodotin (belamaf; GSK2857916) in combination with five different novel agents in patients with relapsed/refractory multiple myeloma (RRMM)","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Interim analysis; Cohort; Oncology; Refractory (planetary science); Dosing; Internal medicine; Multiple myeloma; Biomarker; Adverse effect; Combination therapy; Lenalidomide; Interim; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001211321,0.001031996,0.001948202,0.0004118956,0.0003222146,0.001269058,0.0009523614,0.000728946,0.005145217],"category_scores_gemma":[0.0006535016,0.0004127336,0.001794152,0.0003967161,0.0006937707,0.001032317,0.0005578607,0.003109585,0.001070288],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001643061,"about_ca_system_score_gemma":0.001334545,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00129413,"about_ca_topic_score_gemma":0.004934982,"domain_scores_codex":[0.9996289,0.0001285021,0.0000247895,0.00006946906,0.00004240346,0.0001059368],"domain_scores_gemma":[0.9997322,0.0000347558,0.00004594736,0.00002243327,0.00001469394,0.0001499065],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6894149,0.007957327,0.00549166,0.00191645,0.004644634,0.0003345026,0.0002235119,0.004809784,0.01232554,0.001894463,0.01698366,0.2540035],"study_design_scores_gemma":[0.7885849,0.1649522,0.01657008,0.0002175239,0.002444425,0.0007607029,0.0001065602,0.003524098,0.003161908,0.001214019,0.01837407,0.00008945846],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9725775,0.011112,0.0007651029,0.002242082,0.0006195307,0.0008879175,0.00251304,0.0003420587,0.008940874],"genre_scores_gemma":[0.9836974,0.003657858,0.001328939,0.001322895,0.0002770463,0.0007184552,0.003549407,0.00003498674,0.005412946],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005145217,"threshold_uncertainty_score":0.01721251,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04562237161427093,"score_gpt":0.3188402669338923,"score_spread":0.2732178953196214,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}